{"name":"Acorda Therapeutics","slug":"acorda-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fampridine-SR","genericName":"Fampridine-SR","slug":"fampridine-sr","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Fampridine-SR","genericName":"Fampridine-SR","slug":"fampridine-sr","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPdm1LczFlN25RMzEzYkJGUWsyM1poMHFVcHM0VmFuQ0NKdU9rRzk1SXUxR0t1V3piZVBmaXBOSHpHTEtyeE1iN1lHWGpaUy1ISUlYMHNjUWM5eVFHQ2VZTzRVV1hMb1pjSHhrcHZPWXZWZkxzQXlrUFlGclkwdlZaUk96V3liRFk?oc=5","date":"2025-12-11","type":"pipeline","source":"Yahoo Finance","summary":"$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players - Yahoo Finance","headline":"$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Al","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxPRUVmNFlIZEd3NG50a2p6Z1hWSUI0UnpydUNDWk1VQXNiQ2V4M0s2aGl0LVl6V3lud0JVWWpDTTVTejY2bWktMXVRU2tBR245c2RDSFlTNFZXa1k1YnhzSThQSjZfWXllZmVjQlpJc3c4LWRsVm1wSFZ1UXMtUGt3UEpuN0FQNEt2VVh3SnF5YUhNeTc5eUItcDI4Tzg1dFRacEVZbDB0Z21zU19KeXlzRmU1Umg5TjBPZmh0V1Z1bFYxd3lQT01DVDhlS0FNZklZY3QwSkJpSFlYQXNIRjdCMjRKa3JpTHhLemIwcGhOWlNHNHdfNVlXc0J0OXY5andiLXZBbzRDVFFabkdS?oc=5","date":"2025-12-03","type":"pipeline","source":"VitalLaw.com","summary":"FRAUD AND MANIPULATION—S.D.N.Y.:... - VitalLaw.com","headline":"FRAUD AND MANIPULATION—S.D.N.Y.:...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQek5Fdk5GRzNvdWwwR1pNNzIzM3Rka2pmOHZpWG4yY2w2WlNyUnN3Z1JBRERqOXZUaUhLd2pnN0tlYzlSdVlRZHBlYk1zZ0NqU2hIY0c0eUsxTzFmOUVSTVlVSWJadXYxU3VVSFA0cGhMcHlDTEs2MEtxZTQwUThSNHpPR0RzTUdMNVpvRXZ0ai14MkhndDBVdm9GLU1WX19kdWp5LUtfTUN2Q2Z2MXNMWlpiNVp6Zw?oc=5","date":"2025-01-30","type":"patent","source":"IPWatchdog.com","summary":"CAFC Applies Minimum Contacts Analysis of Acorda to Infringement Case Over Eylea Biosimilar - IPWatchdog.com","headline":"CAFC Applies Minimum Contacts Analysis of Acorda to Infringement Case Over Eylea Biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQQVRUWFQyQUpOSG1FYnc5WEtmUWRQcHZJYWdYeHZCTW4zWnQyRHJoODhwR0lfUk9KTzBsLUVJcTRGQVJpYnBldkNqVjRiZnpkZFN0alduWExaVkpjZ2xKM3U5Y1I1RHZ3RVluZG1kSlc2TUhVSjVaOVNORkNsbWZnei1RLUh4WFZqS0dybWRxeTUtR1FaWDFvUnpDVHByMlN1aWdCeTI0UnlwbHdLdDRON2p6dEEzTjd6aXZISW1iOGpwRTNmcmFxWUpNWmZUWTZoQkQyZjFR?oc=5","date":"2024-07-10","type":"pipeline","source":"businesswire.com","summary":"Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics - businesswire.com","headline":"Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNcEY2Z0p6cnlIbWhFczRnU0FXNU13VEhseVg5U1Z4eVhjXzYtUjFRRTlWcXU2RmhDbEFaRVpjSklVLWxpUFJhRjVyVHdxc0dfS25peUZCeDZRXzd2b1o4MVZ6LW52YWpfRjIteE05cG8xSWRJUEV0WnJyczJTMzFyNkRvbFVZWGlIZ0tFRnNfVDhDOTJDY3VlMlh2NA?oc=5","date":"2024-04-16","type":"pipeline","source":"Pharmaceutical Technology","summary":"Acorda loses Nasdaq listing to cap biotech’s end - Pharmaceutical Technology","headline":"Acorda loses Nasdaq listing to cap biotech’s end","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPUXlYYldwSF9EMTFXUlpkSEdlMDAyQzZIT2FVZ2FCcm5QS0dTalE4cjdoNDY3a3BnQTVEbHNHTjQ2Qm1YV2wydG5MS1Bic2wtbUp6cWNWeFYyeEo4aDQxTUhjMVFkMFJvQmxJTnFSUUhtdjhaNTltVGlFNmFRUHFCUU1zQWVUNGFnOFpTZDh3MkFNRUdla1dXNTI4WjJPSk9VMmNLcEJoR053R3lYLVk1eUtwNjNFRHpheEhHd2F0NVNxZw?oc=5","date":"2024-04-09","type":"pipeline","source":"Fierce Pharma","summary":"UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales - Fierce Pharma","headline":"UPDATED: Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVktkODdKdWx2X1FxVTFLdnRVVXpOSEY2d0xDU3VZdHpDbTBZOHNleXlGTjR5TTJ3R2t1a3ZzSWxQU2U1a1d4YUZXU0xtYWRRd3RxZHpJV0RCUWlOdm5tQTg1aEZPMF9OcE10UnFTYjBzWGstNUhRelVwRm8yV3k5ZDdwV29sSm1Vck9XUi1STWtaeUFaUzhHa3JJQ2poTWJIdmNLa1FIMndxMXlmNWFxSlozMHFaaS1jdk9hVXVCTUVCZXlsWWNjcFU4UjdjUmJwOU1UblVsQ2tWMU8zVnFWbll1SkJfVF83?oc=5","date":"2024-04-08","type":"pipeline","source":"The Journal News | lohud.com","summary":"Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com","headline":"Pearl River-based Acorda Therapeutics to close; 97 jobs impacted - The Journal News | lohud.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPWXdlVVlXUW5McENpWVpzM2NZYVhZQ19RU25OWFZ2NHRZZF9oeTB5RTJrUm1iRHQzNzY0Q253czBTVGNVZEpmTnFuSVF1TXA1S2M1V2dZM2wzUVp2bTlTYzg5d2F4QktQN3dSUUU4NTZTTWxaZzdRU29aYnhGZ0FwTzVYU1E5X3FHUDRrU1JOSEt0dEN2MHc?oc=5","date":"2024-04-02","type":"pipeline","source":"BioPharma Dive","summary":"Acorda files for bankruptcy, reveals asset sale plan - BioPharma Dive","headline":"Acorda files for bankruptcy, reveals asset sale plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5vWURTN3lueWtBVHJXMzBCUTAxYXJRWGRRZ0lqcFJZVjlQQlZya1BsU3NHczI0ZmNjOF92WHJTeV8tZnJyOElGYjNET3VFXzZVNnEzT3hYU2VoY2x2MlRPMjZ0YU43TVpSRW93alUyMDBHQjFicmZGaU1vaWR4SjA?oc=5","date":"2024-04-02","type":"deal","source":"businessnc.com","summary":"Merz Therapeutics buying two drugs for $185 million - businessnc.com","headline":"Merz Therapeutics buying two drugs for $185 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOSEZiY3ZMS3hDQnVoc1dwYUtTR2VGUmtVcFNPQlNqRjlxWGNJclYtX0tQSW56VWNsRWIwU0U0c2hZN3NuRElRUWIwaXU4MGtYcnp3VGNiT0RHMVg0Q185RHI0RlY0dE5kV24tYjFTdkNnSHhTd3J2Q1JyZlk1aWRuTV9fQzM5bW56WUdSQVQ2NkJuWWFZYmVJY184VVpiQVdKZDJ3dldHdmZlOXVKZ1BQMVp1bjdWaDBMVmQxLTZRc1FTYnBMQUxrMjgwdFRCVFBJVktmdURVeHVHVXp5ZFFjQm11My1weExLUnlISjh3?oc=5","date":"2023-05-08","type":"pipeline","source":"PR Newswire","summary":"Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China - PR Newswire","headline":"Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYm1GTlJIM3gxWFo1OW4xNU56bHZsOGl5a1NUNkpBOTZXaXY5Nm1TSGxSd0wzVENoQ1p6Q25wZTkxN3JyZ2lYT1hiRGgydC02Mk1qZ2tMNWNJTzV3VFZ4Y0dsQWxPeWtGYTVBdFpKLVI3Z2ZMbzJXYy14ZVA0eFJ5SHNpNm53YVlESFY1Q0VJbTRPU2R2cl9TampVSm9GT1MwY25GSm1lRzRmZw?oc=5","date":"2021-02-19","type":"pipeline","source":"drugdeliverybusiness.com","summary":"Acorda Therapeutics announces departure of business operations chief - drugdeliverybusiness.com","headline":"Acorda Therapeutics announces departure of business operations chief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNYnhDU2FRZWgtaE1EbnF3ZE5MQ2JiQ2h2d2l0OVhVd0lVR25ENDlCYkxjb3RGeG5lU1hWNjVmM3Vmem9mLXdZeWQxNlBMSFUwYVNkS1dwRWlrbjhmR3g4cU9fd2NLS0lwSjlqX01URXF4QWNsMlR0eHFfVncxS2R3eTI5aUFRVU9jaFNKR015VXBiQUd6Mk9kb0hMYXlzZXVJc29oaUpPRQ?oc=5","date":"2021-01-13","type":"deal","source":"Contract Pharma","summary":"Catalent Acquires Acorda’s INBRIJA Manufacturing Operations - Contract Pharma","headline":"Catalent Acquires Acorda’s INBRIJA Manufacturing Operations","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}